Daniel Catenacci, MD, University of Chicago, Chicago, IL, outlines the findings of a Phase II study evalating individualized treatment strategies for patients with metastatic gastroesophageal adenocarcinoma. Individually optimizing chemotherapy, biomarker profiling, and matching of targeted therapies resuled in improved outcomes when compared to historical controls. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.